Skip to main content
Clinical Trials/NL-OMON48830
NL-OMON48830
Completed
Not Applicable

A phase I study assessing the safety and performance of VB5-845D-800CW, an anti-Epcam fluorescent agent, for the intraoperative detection of gastrointestinal cancer - Intra-operative imaging of gastrointestinal cancer using VB5-845D-800CW

eids Universitair Medisch Centrum0 sites34 target enrollmentStarted: TBDLast updated:

Overview

Phase
Not Applicable
Status
Completed
Enrollment
34

Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • Part A (healthy volunteers)
  • A maximum of sixteen (16\) healthy volunteers will take part in this study.
  • Inclusion criteria
  • 1\) The subject is 18\-65 years old at screening.
  • 2\) The subject is able and willing to comply with study procedures, and signed
  • and dated informed consent is obtained before any study\-related procedure is
  • 3\) Female subjects need to be surgically sterile, post\-menopausal or
  • pre\-menopausal with a negative urine pregnancy test at screening and just
  • before administration of VB5\-845D\-800CW. Pre\-menopausal female subjects have to
  • agree to use an effective method of contraception for 90 days after

Exclusion Criteria

  • Part A (healthy volunteers)
  • A maximum of sixteen (16\) healthy volunteers will take part in this study. ,
  • Exclusion criteria
  • 1\) Female subjects that are lactating or pregnant.
  • 2\) Unacceptable known diagnoses or diseases at baseline, e.g., known
  • cardiovascular or pulmonary disease, renal or liver dysfunction, ECG or
  • laboratory abnormalities, etc.
  • 3\) Use of prescription drugs, with the exception of contraceptive drugs.
  • 4\) Participation in a clinical trial within 90 days of screening or more than 4
  • times in the previous year.

Investigators

Similar Trials

Completed
Not Applicable
A Phase I Study Assessing the Safety and Performance of SGM-101, a Fluorochrome-Labeled Anti-Carcinoembryonic Antigen Monoclonal Antibody for the Intraoperative Detection of Neoplastic Lesions in Patients with Cancer of the Colorectum or Pancreas
NL-OMON47359Surgimab85
Recruiting
Not Applicable
Study on the detection of cancer during surgery for rectal cancer or pancreatic cancer with the fluorescent agent SGM-101 'rectal cancerpancreatic cancer
NL-OMON21037eiden University Medical Center (LUMC) and Centre for Human Drug Research (CHDR), Leiden, the Netherlands30
Recruiting
Not Applicable
A phase I study assessing the safety and performance of VB5-845D-800CW, an fluorescent agent, for the intraoperative detection of gastrointestinal cancer
NL-OMON27469eiden University Medical Center (LUMC)34
Active, not recruiting
Phase 1
A Phase I/II study to evaluate Trappsol Cyclo (hydroxypropyl-ß-cyclodextrin) in patients with Niemann-Pick disease type C (NPC-1) to assess what the drug does to the body, and what the body does to the drug, and the side effects and benefits experienced by patientsiemann-Pick disease type CMedDRA version: 20.0Level: PTClassification code 10029403Term: Niemann-Pick diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
EUCTR2015-005761-23-SECyclo Therapeutics, Inc.11
Active, not recruiting
Phase 1
A Phase I/II study to evaluate Trappsol Cyclo (hydroxypropyl-ß-cyclodextrin) in patients with Niemann-Pick disease type C (NPC-1) to assess what the drug does to the body, and what the body does to the drug, and the side effects and benefits experienced by patientsiemann-Pick disease type CMedDRA version: 20.0 Level: PT Classification code 10029403 Term: Niemann-Pick disease System Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
EUCTR2015-005761-23-GBCTD Holdings, Inc.12